MDT

96.91

-0.67%↓

147.87

-0.47%↓

VEEV

232.45

-3%↓

HQY

84.34

-10.55%↓

PHR.US

17.13

-0.23%↓

MDT

96.91

-0.67%↓

147.87

-0.47%↓

VEEV

232.45

-3%↓

HQY

84.34

-10.55%↓

PHR.US

17.13

-0.23%↓

MDT

96.91

-0.67%↓

147.87

-0.47%↓

VEEV

232.45

-3%↓

HQY

84.34

-10.55%↓

PHR.US

17.13

-0.23%↓

MDT

96.91

-0.67%↓

147.87

-0.47%↓

VEEV

232.45

-3%↓

HQY

84.34

-10.55%↓

PHR.US

17.13

-0.23%↓

MDT

96.91

-0.67%↓

147.87

-0.47%↓

VEEV

232.45

-3%↓

HQY

84.34

-10.55%↓

PHR.US

17.13

-0.23%↓

Inicio・Lista de Acciones・Anavex Life Sciences Corp

Anavex Life Sciences Corp

Cerrado

SectorSalud

4.28 0.23

Comprar Vender

Resumen

Variación precio

24h

Actual

Mínimo

4.08

Máximo

4.32

Métricas clave
By Trading Economics
Ingresos	3.4M -9.8M
Empleados	34
EBITDA	-2.1M -13M

Recomendaciones
By TipRanks
Recomendaciones	Comprar
Estimación a 12 meses	+368.38% upside

Dividendos
By Dow Jones
Próximas Ganancias	11 feb 2026

Estadísticas de Mercado
By TradingEconomics
Capitalización de Mercado	88M 353M
Apertura anterior	4.05
Cierre anterior	4.28

Noticias sobre sentimiento de mercado

By Acuity

50%

173 / 370 Clasificación en Healthcare

Puntuación técnica

By Trading Central

Confianza

Very Strong Bearish Evidence

8.275 / 9.312 Soporte y Resistencia

Anavex Life Sciences Corp Gráfico

El rendimiento pasado no es un indicador fiable de resultados futuros.

Noticias Relacionadas

12 ene 2026, 23:54 UTC

Charlas de Mercado

CBA Could Underperform Again in 2026 -- Market Talk

12 ene 2026, 23:48 UTC

Charlas de Mercado

Global Forex and Fixed Income Roundup: Market Talk

12 ene 2026, 23:48 UTC

Charlas de Mercado

Nikkei May Rise on Weaker Yen -- Market Talk

12 ene 2026, 23:43 UTC

Charlas de Mercado

Gold Edges Lower on Likely Technical Correction -- Market Talk

12 ene 2026, 23:18 UTC

Adquisiciones, fusiones, absorciones

Paramount Sues Warner Bros., Plans Proxy Fight. The Ellisons Aren't Giving Up. -- Barrons.com

12 ene 2026, 21:56 UTC

Charlas de Mercado

Light & Wonder Gets Positive Outcome From Lawsuit -- Market Talk

12 ene 2026, 21:50 UTC

Charlas de Mercado

Basic Materials Roundup: Market Talk

12 ene 2026, 21:50 UTC

Charlas de Mercado

Health Care Roundup: Market Talk

12 ene 2026, 21:50 UTC

Charlas de Mercado

Ganancias

Auto & Transport Roundup: Market Talk

12 ene 2026, 21:18 UTC

Charlas de Mercado

Global Equities Roundup: Market Talk

12 ene 2026, 21:18 UTC

Charlas de Mercado

Pfizer CEO Sees Large Cash Market for Obesity Drugs -- Market Talk

12 ene 2026, 20:54 UTC

Ganancias

Gap, Fortinet, and More Stocks That Usually Outperform After Earnings -- Barrons.com

12 ene 2026, 20:48 UTC

Charlas de Mercado

Oil Futures Settle Higher in Choppy Trade -- Market Talk

12 ene 2026, 20:33 UTC

Charlas de Mercado

U.S. Natural Gas Jumps on Colder Weather Outlook -- Market Talk

12 ene 2026, 20:18 UTC

Adquisiciones, fusiones, absorciones

Credit Agricole Sees Banco BPM Stake Helping 2025 Net by EUR200M >ACA.FR

12 ene 2026, 20:18 UTC

Adquisiciones, fusiones, absorciones

Credit Agricole: European Central Bank Approves Crossing of 20% Threshold in Share Capital of Banco BPM

12 ene 2026, 19:39 UTC

Charlas de Mercado

J&J CEO: Trump Pact Allows Company to Focus on Core Operations -- Market Talk

12 ene 2026, 19:36 UTC

Charlas de Mercado

Gold and Silver Set New Records on Fed Probe -- Market Talk

12 ene 2026, 19:36 UTC

Charlas de Mercado

Global Forex and Fixed Income Roundup: Market Talk

12 ene 2026, 19:33 UTC

Charlas de Mercado

Venezuela's 'Proven' Oil Reserves Raises Questions -- Market Talk

12 ene 2026, 19:24 UTC

Adquisiciones, fusiones, absorciones

Dynavax: 'Party A' CEO Sent a Non-Binding $15/Shr Proposal on Dec. 23

12 ene 2026, 19:22 UTC

Adquisiciones, fusiones, absorciones

Dynavax Files Tender Offer Recommendation Statement Related to Sanofi Deal, Mentions Talks With 'Party A'

12 ene 2026, 18:21 UTC

Adquisiciones, fusiones, absorciones

Paramount Plans Proxy Fight to Push Hostile Warner Bid -- 2nd Update

12 ene 2026, 18:20 UTC

Adquisiciones, fusiones, absorciones

This French Biotech Stock Surged 1,700% in 2025. Eli Lilly Is Taking an Interest. -- Barrons.com

12 ene 2026, 18:19 UTC

Charlas de Mercado

Modest Canadian Economic Impact Seen from Venezuela Changes -- Market Talk

12 ene 2026, 18:16 UTC

Charlas de Mercado

Adquisiciones, fusiones, absorciones

Comcast Could Unlock Value With a Spinoff of NBCUniversal Assets, Analysts Say -- Market Talk

12 ene 2026, 18:09 UTC

Charlas de Mercado

Global Equities Roundup: Market Talk

12 ene 2026, 18:09 UTC

Charlas de Mercado

Baidu's Outlook Bodes Well For Shares -- Market Talk

12 ene 2026, 18:01 UTC

Adquisiciones, fusiones, absorciones

QXO Is Raising Another $1.8 Billion for Its M&A War Chest -- Barrons.com

12 ene 2026, 18:00 UTC

Charlas de Mercado

Canada's 'Breakeven' Employment Recalibrating -- Market Talk

Comparación entre iguales

Cambio de precio

Anavex Life Sciences Corp Esperado

Precio Objetivo

By TipRanks

368.38% repunte

Estimación a 12 meses

Media 20 USD 368.38%

Máximo 20 USD

Mínimo 20 USD

De acuerdo con 2 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para Anavex Life Sciences Corp Dist en los últimos 3 meses.

Consenso

By TipRanks

Comprar

2 ratings

Comprar

Mantener

Vender

De acuerdo con 2 analistas que ofrecen calificaciones bursátiles a para Anavex Life Sciences Corp Dist en los últimos 3 meses.

Puntuación técnica

By Trading Central

8.275 / 9.312Soporte y Resistencia

Recent bearish events outweigh bullish events.

Recent bullish events outweigh bearish events.

The bullish and bearish events are balanced.

Sentimiento

By Acuity

173 / 370 Clasificación en Salud

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

Acerca de Anavex Life Sciences Corp

Anavex Life Sciences Corp., a clinical stage biopharmaceutical company, engages in the development of therapeutics for the treatment of central nervous system diseases. Its lead product candidate is ANAVEX 2-73 for the treatment of Alzheimer's disease and Parkinson's disease, as well as other central nervous system diseases, including rare diseases, such as Rett syndrome, a rare severe neurological monogenic disorder; and infantile spasms, Fragile X syndrome, and Angelman syndrome. The company's drug candidate also comprises ANAVEX 3-71, which is in clinical trial for the treatment of schizophrenia, frontotemporal dementia, and Alzheimer's disease. Its preclinical drug candidates include ANAVEX 1-41 for the treatment of depression, stroke, and neurogenerative disease; ANAVEX 1066 for the potential treatment of neuropathic and visceral pain; and ANAVEX 1037 to treat prostate and pancreatic cancer. The company was incorporated in 2004 and is headquartered in New York, New York.